Entasis Therapeutics to Participate in the 5th Annual SunTrust Robinson Humphrey (STRH) Annual Life Sciences Summit
April 30 2019 - 4:01PM
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of novel antibacterial products, today announced that Dr. Manos
Perros, President and Chief Executive Officer of the Company, will
host one-on-one meetings with investors at the 5th Annual SunTrust
Robinson Humphrey (STRH) Annual Life Sciences Summit being held May
7-9, 2019 in New York, New York.
Investors attending the conference who are
interested in meeting with Company management should contact their
STRH representatives.
About EntasisEntasis is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of novel antibacterial products
to treat serious infections caused by multidrug-resistant
Gram-negative bacteria. Entasis’ targeted-design platform has
produced a pipeline of product candidates, including ETX2514SUL
(targeting A. baumannii infections), zoliflodacin (targeting
Neisseria gonorrhoeae), and ETX0282CPDP (targeting
Enterobacteriaceae infections). Entasis is also using its platform
to develop a novel class of antibiotics, non-β-lactam inhibitors of
the penicillin-binding proteins (NBPs) (targeting Gram-negative
infections). For more information, visit www.entasistx.com.
Entasis Company Contact Kyle
Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com
Investor Relations ContactTram BuiThe Ruth
Group(646) 536-7035tbui@theruthgroup.com
Media ContactKirsten ThomasThe Ruth Group(508)
280-6592kthomas@theruthgroup.com
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Apr 2023 to Apr 2024